Controversial vaccine trial touted by RFK Jr gets go-ahead in Guinea

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-10-09T21:51:26.409Z • Permanent link

Danish researchers have received the green light to conduct a groundbreaking vaccine trial in Guinea, sparking controversy over the withholding of hepatitis B vaccines from thousands of newborns. Robert F. Kennedy Jr., a prominent anti-vaxxer, has been vocal about his support for the trial, which is being led by the International Medical Volunteer Corps (IMVC) in collaboration with the Guinea Ministry of Health.

The trial, set to begin in 2024, will involve withholding the recommended dose of the hepatitis B vaccine from newborns in Guinea, with the aim of studying the effects of the vaccine on the development of autism and other neurological disorders. Kennedy, who has been a vocal critic of vaccine policies, has been a key proponent of the trial, claiming that the vaccine is linked to increased rates of autism and other health problems.

Critics have raised concerns about the trial's methodology and the risks associated with withholding vaccines from newborns. Dr. Peter Hotez, a leading expert on vaccine development, has warned that the trial could have serious consequences for public health, particularly in a country with limited healthcare resources. "This trial is a recipe for disaster," Hotez said in a statement. "We have a clear understanding of the risks of hepatitis B vaccine, and withholding it from newborns will only increase the risk of disease transmission.

The implications of this trial are far-reaching, with significant consequences for the AI & Tech Ecosystems domain. The trial's focus on the potential links between vaccines and neurological disorders has sparked heated debate within the scientific community, with many experts arguing that the evidence is not yet conclusive. The trial's methodology has also raised concerns about the potential impact on vaccine development, with some experts warning that the trial could lead to a re-evaluation of vaccine policies and a decrease in vaccine uptake.

The trial's potential impact on the pharmaceutical industry is also significant, with several major vaccine manufacturers expressing concerns about the trial's methodology and the potential consequences for their products. Pfizer, for example, has stated that it is "concerned" about the trial's focus on the potential links between vaccines and neurological disorders, citing the need for rigorous scientific evidence to support any claims about vaccine safety. "We are committed to the safety and efficacy of our vaccines," a Pfizer spokesperson said in a statement. "Any trial that raises concerns about vaccine safety will be closely monitored.

This trial is part of a larger pattern of controversy surrounding vaccine development and policy in Africa. In recent years, several high-profile vaccine trials have been conducted in Africa, with some critics arguing that these trials have been rushed and that the rights of participating populations have been compromised. The trial in Guinea is also part of a broader debate about vaccine equity and access, with many experts arguing that vaccines should be made available to all populations, regardless of income or geography.